| Old Articles: <Older 6511-6520 Newer> |
|---|
 |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.   |
The Motley Fool
July 30, 2010
Brian Orelli |
It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis. |
The Motley Fool
July 30, 2010
Anand Chokkavelu |
5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
July 30, 2010
Brian Orelli |
MannKind: Strengths, Weaknesses, Opportunities, Threats It's all about the inhaled insulin. |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
The Motley Fool
July 30, 2010
Brian Orelli |
On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually. |
The Motley Fool
July 29, 2010
Brian Orelli |
Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company. |
The Motley Fool
July 29, 2010
Brian Orelli |
This Best Biotech Is Cheaper Than You Think The cancer-drug specialist justifies its valuation quite effectively with a stellar second-quarter performance. |
The Motley Fool
July 29, 2010
Brian Orelli |
Buy, Sell, or Hold: Biotech Generics Generic biotech drugs are coming. Hop on. |
| <Older 6511-6520 Newer> Return to current articles. |
